IPG Photonics has made a binding offer to acquire Lumibird Medical, strengthening its position in ophthalmology and the medical-laser market. The proposed acquisition values Lumibird Medical at €300 million on a cash-free, debt-free basis. An additional earn-out of up to €50 million is linked to performance targets for 2026 and 2027, taking the potential total consideration to €350 million. If completed, the deal would combine IPG Photonics’ laser and photonics expertise with Lumibird Medical’s ophthalmology portfolio and global commercial network.
The key figures behind the transaction include:
IPG Photonics plans to fund the acquisition with existing cash, with completion expected in the fourth quarter of 2026, subject to employee consultation, regulatory approvals and customary closing conditions.
Lumibird Medical has built an established international position in ophthalmic diagnostics and laser-based treatment through its Quantel Medical, Ellex and Optotek Medical brands. Its portfolio supports the diagnosis and treatment of several major eye conditions, including glaucoma, cataracts, retinal disease, dry eye and age-related macular degeneration. The business also operates across ophthalmic ultrasound and other specialist diagnostic technologies. Lumibird Medical’s revenue is distributed across several major international markets:
This geographic reach would give IPG access to an established global customer base spanning hospitals, ambulatory surgery centres, ophthalmologists, optometrists and other eye-care professionals.
IPG Photonics already has an established presence in medical applications, particularly within urology and dermatology. Lumibird Medical would add a leading ophthalmology capability, creating a broader platform across three of the most significant medical-laser specialities. According to IPG, the combined medical operation would have generated approximately $204 million in pro forma sales during 2025. It is also expected to expand the addressable market for its Advanced Solutions division by around $1 billion. Beyond increasing scale, IPG sees opportunities to combine the two companies’ technical and commercial strengths. This could include jointly developing new products and integrating IPG-manufactured lasers, optics and photonics components into future medical systems.IPG expects the acquisition to be accretive to gross margin, EBITDA and adjusted earnings per share.
For Lumibird, the transaction would create a more focused photonics group operating across defence, space, industrial, scientific, environmental and sensing markets. Following the proposed sale, the remaining Photonics Division would have reported 2025 sales of €113.4 million and more than 600 employees. Lumibird intends to use the proceeds to reduce debt while increasing investment in research and development, manufacturing capabilities and international expansion. The transaction may also provide flexibility to return a portion of the proceeds to shareholders. Lumibird believes IPG’s scale, industrial capabilities and long-term investment capacity could support the Medical Division’s next stage of innovation and international development.
The proposed IPG Photonics and Lumibird Medical acquisition reflects the growing strategic importance of ophthalmology businesses that combine differentiated technology with clinical credibility, regulatory expertise and global distribution. Ophthalmology continues to benefit from long-term demand driven by ageing populations, increasing rates of sight-threatening conditions and wider access to advanced diagnostic and treatment technologies. For established photonics and medical-device companies, acquiring proven ophthalmology platforms can provide a faster route into highly specialised markets where product performance, regulatory approval, practitioner trust and commercial infrastructure create significant barriers to entry. Transactions of this scale can also reshape the market for leadership talent. Integrating international portfolios requires experienced commercial, clinical, regulatory, product and operational leaders who can translate technical capabilities into sustainable growth. Completion is not yet assured. IPG Photonics has submitted a binding offer, and Lumibird has entered exclusive negotiations for the sale of its Medical Division, but the deal still depends on employee consultation, regulatory approvals and customary closing conditions. Nevertheless, the proposed transaction represents a significant development for both the ophthalmology and global medical-laser sectors, so now is the time for industry leaders, investors and talent to assess the implications, engage with emerging opportunities and position themselves for the next phase of growth.